Yield10 Bioscience Announces Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops more than 4% on talks aimed at ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Iran, Qatari mediators hold third day of talks to end US-Iran war
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Yield10 Bioscience, Inc. (YTEN) Tops Q2 EPS by 38c
August 11, 2020 4:21 PM EDTYield10 Bioscience, Inc. (NASDAQ: YTEN) reported Q2 EPS of ($0.92), $0.38 better than the analyst estimate of ($1.30). Revenue for the quarter came in at $221 thousand versus the consensus estimate of $180 thousand.
"The Yield10 team has made good progress executing on our strategic plans for 2020 and beyond," said Oliver Peoples, Ph.D., president and chief executive officer of Yield10 Bioscience. "Our field tests in the U.S. and Canada are progressing on track and will provide us with agronomic... More



